Results 81 to 90 of about 1,349 (113)

Investigations of remibrutinib in models pertinent to multiple sclerosis. [PDF]

Neurotherapeutics
Jain RW, Rayatpour A, Hagen K, Morch MT, Randhawa G, Mobarakabadi M, Zhang X, Li C, Nakhaei-Nejad M, Giuliani F, Cenni B, Xue M, Yong VW.   +12 more
europepmc   +1 more source

Case Report: X-linked agammaglobulinemia with progressive neurodegeneration from immunological to neurological implications. [PDF]

Front Immunol
Chen X, Gu H, Piao Y, Ma Y, Zhao Y, Mao H, Wang Y, Deng J.   +7 more
europepmc   +1 more source

Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events. [PDF]

Cancer Med
Obeng-Kusi M, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, Jiao W, Hyatt HW, Zhang X, Lodaya K, Dingli D.   +10 more
europepmc   +1 more source

Case Report: dose adjustment of orelabrutinib for managing central nervous system post-transplant lymphoproliferative disorder following acute lymphoblastic leukemia transplantation. [PDF]

Front Immunol
Wang W, Chen J, Guan L.
europepmc   +1 more source

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma. [PDF]

Blood Adv
Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y.   +7 more
europepmc   +1 more source

Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy. [PDF]

Genes (Basel)
Sekeres S, Lamkin EN, Bravo E, Cool A, Taylor J.   +4 more
europepmc   +1 more source

Evaluating remibrutinib in the treatment of chronic spontaneous urticaria. [PDF]

Immunotherapy
Bożek A, Reich A.
europepmc   +1 more source

Bruton tyrosine kinase inhibitor in non-IgM lymphoplasmacytic lymphoma: a case report and literature review. [PDF]

J Clin Exp Hematop
Ito K, Hirano K, Sekiguchi N.
europepmc   +1 more source

Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges. [PDF]

Ann Hematol
Wang Y, Zhang Y, Liu J, Jiang Y, Li J, Shi W.   +5 more
europepmc   +1 more source

BTK autoinhibition analyzed by high-throughput swaps of SH2 domains. [PDF]

Proc Natl Acad Sci U S A
Eisen TJ, Ghaffari-Kashani S, Hung CL, Groves JT, Kuriyan J.   +4 more
europepmc   +1 more source